The Government of Australia has announced new funding of $100m to advance brain cancer research as part of efforts to provide a better life to people suffering from the disease.

Formed as an alliance between the Federal Government, philanthropists, medical experts, patients and their families, the Australian Brain Cancer Mission is intended to double patient survival rates over the coming decade.

Initially, the government is awarding $50m through the Medical Research Future Fund (MRFF) and $10m from the Minderoo Foundation’s Eliminate Cancer Initiative.

Additionally, $20m is provided from Cure Brain Cancer Foundation, with plans to issue the remaining $20m in the near future.

The mission is set to leverage a research plan developed by the Australian and international brain cancer treatment and research experts in collaboration with patients and their advocates.

“With an aim to provide clinical trial participation opportunity for every patient in the country, the mission intends to invest in clinical trials and new network for discovery.”

With an aim to provide clinical trial participation opportunity for every patient in the country, the mission intends to invest in clinical trials and new network for discovery.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Furthermore, the Australian Brain Cancer Mission is planning for additional international partnerships, expansion of research platforms and technologies, and promotion of research talent.

An arm of the international adaptive trial platform, GBM AGILE, will be established in the country for adults with glioblastoma.

The government has further decided to fund clinical trial centres of Australian and New Zealand Children’s Haematology Oncology Group (ANZCHOG) and provide support for consolidation of the national ZERO Children’s Cancer initiative.

The mission will be administered by a Strategic Advisory Group comprising patients, clinicians, researchers, co-investors, industry representatives and Australian Medical Research Advisory Board members.